Edmonton's Aurora Cannabis Inc. (TSX:ACB) (NYSE:ACB) has begun shipments of its medical-use and adult-use softgel capsules. The company made the announcement this morning, and ACB stock is currently in the green up 1.20% on the day.
Let's take a closer look at this.
ACB Stock Reacts to Softgel Capsules
The company has a sales license from Health Canada to sell softgel capsules, and shipments have already begun across Canada. The capsules are being sent out for medical-use purposes first, with British Columbia the first and only province to also receive them for adult-use purposes. Further provinces will be added in time, and international shipments are expected in early 2019.
A New Market?
One of the most exciting attributes of the Aurora softgel capsules is their smoke-free nature. The expectation is that an entirely new user market may open up for Aurora. Specifically, those who want to consume cannabis without having to inhale or smoke the substance such as non-smokers and the elderly. The easy-to-swallow nature of the softgel capsule will mean they are especially suitable for those who are ill or suffer from lung ailments such as asthma. ACB stock should react in kind to the potential behind this new product.
>> Cannabis Penny Stocks: 48North Cannabis Shines After Canopy Growth Deal
Production
Aurora has big plans for these capsules; the company is creating 1.4 million capsules weekly at its Aurora Vie facility in Quebec. The company obviously notes the potentially huge market for this product and is planning to keep up this large-scale number in order to make the capsules "available to all of its domestic and international target markets over time where legally possible."
Aurora has partnered with its 20% owned softgel manufacturer, Capcium Inc., on this product.
The Aurora Softgel Capsules
Because the capsules are a softgel, they are easily swallowed and digested. Further, they are the smallest cannabis capsule on the market. There will be four types available at first, priced at $45 per bottle of 30. The capsules provide a dosage-controlled format to facilitate precision administration.
As stated, ACB stock is currently up on the news. As these capsules roll-out, this stock could easily rise further.
Featured Image: Depositphotos/© alptraum
